Neuren Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Neuren Pharmaceuticals has been growing earnings at an average annual rate of 80.5%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 82% per year. Neuren Pharmaceuticals's return on equity is 53.5%, and it has net margins of 60.7%.
Key information
80.5%
Earnings growth rate
79.9%
EPS growth rate
Pharmaceuticals Industry Growth | 31.2% |
Revenue growth rate | 82.0% |
Return on equity | 53.5% |
Net Margin | 60.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04Revenue & Expenses Breakdown
How Neuren Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 193 | 117 | 5 | 0 |
31 Mar 24 | 213 | 137 | 6 | 0 |
31 Dec 23 | 232 | 157 | 6 | 0 |
30 Sep 23 | 155 | 106 | 5 | 0 |
30 Jun 23 | 78 | 55 | 4 | 0 |
31 Mar 23 | 47 | 28 | 4 | 0 |
31 Dec 22 | 15 | 0 | 3 | 0 |
30 Sep 22 | 9 | -3 | 3 | 0 |
30 Jun 22 | 3 | -7 | 3 | 0 |
31 Mar 22 | 3 | -7 | 3 | 0 |
31 Dec 21 | 3 | -8 | 2 | 0 |
30 Sep 21 | 2 | -10 | 2 | 0 |
30 Jun 21 | 1 | -12 | 2 | 0 |
31 Mar 21 | 1 | -11 | 2 | 0 |
31 Dec 20 | 1 | -9 | 2 | 0 |
30 Sep 20 | 1 | -8 | 2 | 0 |
30 Jun 20 | 0 | -8 | 2 | 0 |
31 Mar 20 | 0 | -9 | 2 | 0 |
31 Dec 19 | 0 | -11 | 2 | 0 |
30 Sep 19 | 7 | -6 | 2 | 0 |
30 Jun 19 | 14 | -1 | 2 | 0 |
31 Mar 19 | 14 | 1 | 2 | 0 |
31 Dec 18 | 14 | 3 | 2 | 0 |
30 Sep 18 | 7 | 3 | 2 | 0 |
30 Jun 18 | 1 | 3 | 1 | 0 |
31 Mar 18 | 1 | 3 | 2 | 0 |
31 Dec 17 | 1 | 3 | 2 | 0 |
30 Sep 17 | 2 | -2 | 2 | 0 |
30 Jun 17 | 3 | -8 | 2 | 0 |
31 Mar 17 | 3 | -10 | 2 | 0 |
31 Dec 16 | 3 | -12 | 2 | 0 |
30 Sep 16 | 2 | -14 | 2 | 0 |
30 Jun 16 | 0 | -15 | 3 | 0 |
31 Mar 16 | 1 | -14 | 3 | 0 |
31 Dec 15 | 2 | -13 | 3 | 0 |
30 Sep 15 | 2 | -11 | 3 | 0 |
30 Jun 15 | 3 | -9 | 3 | 0 |
31 Mar 15 | 3 | -9 | 3 | 0 |
31 Dec 14 | 3 | -8 | 3 | 0 |
30 Sep 14 | 3 | -10 | 2 | 0 |
30 Jun 14 | 3 | -12 | 2 | 0 |
31 Mar 14 | 4 | -11 | 2 | 0 |
31 Dec 13 | 5 | -10 | 2 | 0 |
Quality Earnings: NEU has high quality earnings.
Growing Profit Margin: NEU's current net profit margins (60.7%) are lower than last year (70.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEU has become profitable over the past 5 years, growing earnings by 80.5% per year.
Accelerating Growth: NEU's earnings growth over the past year (113.1%) exceeds its 5-year average (80.5% per year).
Earnings vs Industry: NEU earnings growth over the past year (113.1%) exceeded the Pharmaceuticals industry 46.5%.
Return on Equity
High ROE: NEU's Return on Equity (53.5%) is considered outstanding.